CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
The CCTG HD11 study, a Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma has closed to accrual. This purpose of this study was to determine if treatment with Pembrolizumab and Brentuximab vedotin is better or worse than the standard of care for classical Hodgkin lymphoma.
For more information > CCTG HD11 members trial page.
CCTG is upgrading our login platform to Auth0 by Okta for a more secure and seamless login experience. The new login screen is designed to be simple and user-friendly, allowing you to log in using your existing credentials. This change ensures faster, more reliable access to your account with fewer sign ins, while keeping your data safe.
Congratulations to Dr. Lesley Seymour, CCTG’s IND Program Director and Deputy Director, on being named a Fellow in the Canadian Academy of Health Sciences (CAHS). Election to the Academy is one of the highest honours in the Canadian health sciences community, recognizing individuals for their exceptional contributions to advancing health research, policy, and care.
"I am honoured to be appointed as a CAHS Fellow and delighted that the contributions of Canadian Cancer Trials Group faculty and investigators have been recognized," says Dr. Seymour.
Please join us in congratulating our friend and colleague, Timothy Whelan on his appointment to the Order of Canada. He is a world-class radiation oncologist and his research has redefined radiation therapy’s use in the treatment of breast cancer, improving survival rates and limiting side effects. He has mentored many trainees, solidifying the reputations of McMaster University and the Juravinski Cancer Centre as leaders in oncology clinical trial training.
The CCTG SR.8 (HARMONY) clinical trial has been awarded almost 1.5 million through the CIHR spring Project Grant Program. Hypofractionated Alternative Radiation with MOdulation of Neoadjuvant/perioperative immunotherapY in Sarcoma is a phase III study that addresses a significant unmet need in the treatment of high-risk soft-tissue sarcoma (STS).
The HE2 (SLIDE-HCC) clinical trial is now open to enrollment and will investigate whether adding an oral anti-angiogenic drug to an existing intravenous immunotherapy combination is more effective than the immunotherapy combination alone for people with liver cancer who have not received prior treatment.
